Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis질병 조절 요법 후 다발성 경화증 환자에서 COVID-19 예방 접종의 반응: 메타 분석Meta-Analysis Published on 2022-07-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 바이오마커, 유전자 메커니즘, [키워드] addressed anti-CD20 anti-CD20 therapy anti-CD20 treatment association benefit booster dose CD20 cellular response Cochrane Library conducted COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines Disease-modifying therapies Efficacy evaluate foundation humoral Humoral response IFN-β immune response literature medRxiv Meta-analysis Multiple multiple sclerosis natural no significant difference Odds ratio Odds ratios other treatment other treatments Patient random-effect receiving receptor required response response to vaccination risk SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines Science Serologic response serological Shanghai significantly higher sphingosine sphingosine-1-phosphate suggested supported T-cell Response therapy Treatment vaccination was performed [DOI] 10.1016/j.ebiom.2022.104102 PMC 바로가기 [Article Type] Meta-Analysis
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational studyObservational Study Published on 2022-06-012023-07-09 Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] COVID19(2023년), [키워드] COVID-19 Disease-modifying therapies fingolimod multiple sclerosis Ocrelizumab outcome measurement. [DOI] 10.1177/13524585221092309 [Article Type] Observational Study
Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis다발성 경화증 환자의 항-COVID19 백신 접종에 대한 항체 매개 반응에 대한 질병 조절 치료의 효과Article Published on 2022-06-012022-09-11 Journal: Journal of Neurology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Adverse adverse event adverse events age aligned analysed anti-CD20 Anti-CD20 antibodies Anti-CD20 antibody anti-CD20 treatment Anti-spike antibody Antibody Response CD19 CD19+ CD20 CD20 deplething therapies cell count cell-mediated immune cell-mediated immune response Cohort correlated COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccines depleting detectable diagnosed Disease-modifying therapies Effect elicited event female fingolimod Follow-up Frequency IgG antibody immune response investigation material median median age Multiple multiple sclerosis non-responders Patient proportion protective immune response Protein receiving recorded Responder responders symptomatic therapy titre treated Treatment vaccination Vaccine was reduced [DOI] 10.1007/s00415-022-11003-3 PMC 바로가기 [Article Type] Article
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in ItalyBNT162b2 백신 후 다발성 경화증 환자의 Anti-Spike IgG: 이탈리아의 탐색적 사례 대조 연구Multicenter Study Published on 2022-02-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] adverse event AEs analyzed anti-spike antibodies antibodies antibody blood sample Blood samples BNT162b2 case-control study Clinical efficacy collected Community Comparisons condition Control COVID-19 COVID-19 vaccine described detect Disease-modifying therapies enrolled evaluated exploratory first dose HCW HCWs healthcare worker IgG Immunosuppressant immunosuppressants implication interquartile range IQR Italy median median and interquartile range Mild mild to moderate moderate multicenter Multiple multiple sclerosis observation Ocrelizumab of BNT162b2 one patient other treatment other treatments Patient patients patients treated performed Pfizer Pfizer-BioNTech receive receiving reduce reduced reported resolved respond scrutiny serological response severity the vaccine therapy treated treated patient treated patients Treatment treatment group vaccination vaccine dose Vaccine, BNT162b2. Vaccines Wilcoxon-Mann-Whitney [DOI] 10.1016/j.msard.2021.103415 PMC 바로가기 [Article Type] Multicenter Study
SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccineBBIBP-CorV(Sinopharm) 비활성화 바이러스 백신 접종 후 질병 조절 요법을 받는 다발성 경화증 환자의 SARS-CoV-2 혈청학: 같은 이야기, 다른 백신Article Published on 2022-01-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] SARS, 치료기술, [키워드] Analysis anti-CD20 therapy anti-SARS-CoV-2 association BBIBP-CorV booster carried Cohort cohort study cohorts contribute COVID-19 COVID-19 vaccines detect Disease-modifying therapies dose Efficiency Evidence fingolimod first vaccination healthy humoral Humoral response humoral responses IgG inactivated indicated investigated Iran less Linear regression mode mRNA Multiple multiple sclerosis multivariable analysis multivariable logistic regression multivariable logistic regression model participant Participants phlebotomy Previous studies previous study receive receptor SARS-CoV-2 seroconverted serology serology testing serostatus Sinopharm sphingosine spike Statistical power Statistical tests t-test therapy vaccination Vaccination strategies Vaccination strategy Vaccine vaccine dose Viral vector Viral vector vaccine Viral vector vaccines virus was used [DOI] 10.1016/j.msard.2021.103417 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies다양한 질병 조절 요법으로 치료받는 다발성 경화증 환자에서 mRNA COVID-19 백신의 면역원성과 안전성Article Published on 2022-01-012022-09-11 Journal: Neurotherapeutics : the journal of the American So [Category] SARS, 진단, 치료기술, [키워드] Alemtuzumab Cladribine correlation COVID-19 COVID-19 vaccination detect develop Disease-modifying therapies drugs evaluated fatigue fingolimod Hospitalization humoral humoral immune response Humoral response IgG immune response immunoassay immunogenicity injection injection site Microparticle MONITOR mRNA COVID-19 vaccine mRNA COVID-19 vaccines Multiple multiple sclerosis Natalizumab Ocrelizumab Pain Patient patients treated positively correlated reduce reported Safe SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 nucleoprotein second dose Side effect significantly lower therapy treated Treatment vaccination was tested [DOI] 10.1007/s13311-021-01165-9 PMC 바로가기 [Article Type] Article
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatmentsArticle Published on 2021-12-012023-07-11 Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] SARS, [키워드] COVID-19 Disease-modifying therapies immunology multiple sclerosis [DOI] 10.1177/1352458520971817
Multiple sclerosis and COVID-19: The Swedish experience다발성 경화증과 COVID-19: 스웨덴의 경험Review Published on 2021-09-012022-09-12 Journal: Acta neurologica Scandinavica [Category] 진단, [키워드] addition anti-CD20 therapy Care Complication concern country COVID-19 COVID-19 pandemic COVID-19 vaccination Disease-modifying therapies groups Health healthcare healthcare management implementation Infection lack management Multiple multiple sclerosis National national guideline off-label outcome measure Patient raised Rapid recent recommendation response risk risk factor risk groups severe COVID-19 Swedish telemedicine consultation therapy [DOI] 10.1111/ane.13453 PMC 바로가기 [Article Type] Review
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic reviewReview Article Published on 2021-01-292023-07-01 Journal: Multiple sclerosis and related disorders [Category] SARS, [키워드] COVID-19 Disease-modifying therapies multiple sclerosis Neuromyelitis optica spectrum disorder [DOI] 10.1016/j.msard.2021.102800 PMC 바로가기 [Article Type] Review Article
Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published CasesReview Published on 2020-12-162022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] acute respiratory syndrome anti-CD20 treatment asked cardiovascular diseases Chronic diseases Coronavirus-2 COVID-19 described disease Disease-modifying therapies experience Healthcare system immunosuppressive therapy information invasive mortality rate Multiple multiple sclerosis non-invasive ventilation outcome pandemic participant Patient patients physician positive Protective reducing required review risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic sclerosis substantial risk the cytokine storm the disease therapy with COVID-19 [DOI] 10.3390/jcm9124067 PMC 바로가기 [Article Type] Review